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Abstract Sphingosine kinase catalyzes the phosphorylation of
sphingosine to form sphingosine 1-phosphate (SPP), a novel lipid
mediator with both intra- and extracellular functions. Based on
sequence identity to murine sphingosine kinase (mSPHK1a), we
cloned and characterized the first human sphingosine kinase
(hSPHK1). The open reading frame of hSPHK1 encodes a 384
amino acid protein with 85% identity and 92% similarity to
mSPHK1a at the amino acid level. Similar to mSPHK1a, when
HEK293 cells were transfected with hSPHK1, there were
marked increases in sphingosine kinase activity resulting in
elevated SPP levels. hSPHK1 also specifically phosphorylated
D-erythro-sphingosine and to a lesser extent sphinganine, but not
other lipids, such as D,L-threo-dihydrosphingosine, N,N-dimethyl-
sphingosine, diacylglycerol, ceramide, or phosphatidylinositol.
Northern analysis revealed that hSPHK1 was widely expressed
with highest levels in adult liver, kidney, heart and skeletal
muscle. Thus, hSPHK1 belongs to a highly conserved unique
lipid kinase family that regulates diverse biological functions.
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1. Introduction
The metabolic product of sphingosine kinase (SPHK),
sphingosine 1-phosphate (SPP), is a lipid signaling molecule
that acts both intra- and extracellularly to a¡ect many bio-
logical processes. These include mitogenesis [1,2], apoptosis
[3], atherosclerosis [4] and in£ammatory responses [5,6]. Spe-
ci¢c members of the EDG-1 family of G protein-coupled re-
ceptors bind SPP (reviewed in [7,8]) and modulate chemotaxis
[9,10], angiogenesis [10^12], neurite retraction and cell round-
ing [13]. Because SPP levels are mainly regulated by the ac-
tivity of SPHK, cloning and characterization of this enzyme
are important for understanding its role in normal and patho-
logical processes. Previously, we puri¢ed SPHK to homoge-
neity from rat kidneys [14] and subsequently identi¢ed mouse
cDNAs encoding two forms of SPHK, designated mSPHK1a
and mSPHK1b, whose predicted proteins di¡er by only 10
amino acids at their N-terminus [15]. The corresponding
mRNAs may arise by alternative splicing. In this study, se-
quence homologies to the mSPHK1a cDNAs were used to
identify and clone the ¢rst human homologue, hSPHK1.
hSPHK1 is ubiquitously expressed in adult tissues with high-
est levels in liver, kidney, lung and skeletal muscle. Our results
suggest that hSPHK1 belongs to a family of highly conserved
enzymes which di¡er from other known lipid kinases.
2. Materials and methods
2.1. Materials
SPP, sphingosine, and N,N-dimethylsphingosine (DMS) were from
Biomol Research Laboratory Inc. (Plymouth Meeting, PA). All other
lipids were purchased from Avanti Polar Lipids (Birmingham, AL).
[Q-32P]ATP (3000 Ci/mmol) was purchased from Amersham (Arling-
ton Heights, IL). Poly-L-lysine was from Boehringer Mannheim (In-
dianapolis, IN). Alkaline phosphatase from bovine intestinal mucosa,
type VII-NT, was from Sigma (St. Louis, MO). Restriction enzymes
were from New England Biolabs (Beverly, MA). Lipofectamine Plus
was from Life Technologies (Gaithersburg, MD).
2.2. Human sphingosine kinase cDNA cloning
BLAST searches using mSPHK1a sequences identi¢ed an EST
clone (AA026479) which contained sequences homologous to several
conserved domains of mSPHK [15]. To obtain a full-length cDNA,
the 5P-end of hSPHK1 was extended by rapid ampli¢cation of cDNA
ends/polymerase chain reaction (RACE-PCR; Life Technologies).
First, cDNA was synthesized from HEK293 poly(A) RNA with a
gene-speci¢c antisense primer hspk1-GSP1 (5P-ACCATTGTCCAGT-
GAG). Then two consecutive PCR reactions using LA Taq (TaKaRa)
were performed. First PCR: 5PRACE Abridged Anchor Primer and
the antisense primer hspk1-GSP2 (5P-TTCCTACAGGGAGG-
TAGGCC) at 94‡C for 2 min followed by 30 cycles of ampli¢cation
(94‡C for 1 min, 55‡C for 1 min, 72‡C for 2 min) and primer exten-
sion at 72‡C for 5 min. Second PCR: Abridged Universal Ampli¢ca-
tion Primer and the antisense primer hspk1-GSP3 (5P-GGCTGCCA-
GACGCAGGAAGG) using a program similar to the ¢rst PCR but
with annealing at 65‡C. The PCR products were cloned into pCR 2.1
(TA Cloning, Invitrogen) and sequences con¢rmed by automated se-
quencing. To make expression constructs, a primer set was designed
as follows: sense primer containing a Kozak sequence and ATG start
codon, sphk1-GSP4 (5P-GCCACCATGGATCCAGCGGGCGGCC-
CC); antisense primer, sphk1-GSP5 (5P-TCATAAGGGCTCTTCTG-
GCGGTGGCATCTG). The PCR reaction was performed using hu-
man fetus Marathon-Ready cDNA (Clontech) as template with the
above primers, and the ampli¢cation product was subcloned into
pCR3.1 (Eukaryotic TA Cloning, Invitrogen). In addition, hSPHK1
was tagged at the N-terminus by subcloning into a pcDNA-c-myc
vector [2] using high ¢delity taq polymerase (Pfu, Stratagene).
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2.3. Cell culture and expression of sphingosine kinase
Human embryonic kidney cells (HEK293, ATCC CRL-1573) were
grown in high glucose Dulbecco’s modi¢ed Eagle’s medium (DMEM)
containing 100 U/ml penicillin, 100 Wg/ml streptomycin and 2 mM
L-glutamine supplemented with 10% fetal bovine serum [15]. Cells
were transfected with either pcDNA3.1 or pCR3.1 containing
hSPHK1 using Lipofectamine Plus according to the manufacturer’s
protocol. Transfection e⁄ciencies were typically about 40%.
2.4. Measurement of sphingosine kinase activity
Cytosolic sphingosine kinase activity was determined with 50 WM
sphingosine, dissolved in 5% Triton X-100 (¢nal concentration
0.25%), and [Q-32P]ATP (10 WCi, 1 mM) containing MgCl2 (10 mM)
as previously described [15]. In some experiments, sphingosine was
added as a complex with bovine serum albumin (BSA) as previously
described [15]. Speci¢c activity is expressed as pmol SPP formed per
min per mg protein.
2.5. Lipid extraction and measurement of SPP, sphingosine, and
ceramide
Cells were washed with phosphate bu¡ered saline and scraped in
1 ml of methanol containing 2.5 Wl concentrated HCl. Lipids were
extracted by adding 2 ml chloroform/1 M NaCl (1:1, v/v) and 100 Wl
3 N NaOH and phases were separated. The basic aqueous phase
containing SPP, and devoid of sphingosine, ceramide, and the major-
ity of phospholipids, was transferred to a siliconized glass tube. The
organic phases were re-extracted with 1 ml methanol/1 M NaCl (1:1,
v/v) plus 50 Wl 3 N NaOH, and the aqueous fractions combined. Mass
measurements of SPP in the aqueous phase were carried out as pre-
viously described [16]. Sphingosine and ceramide in the organic phase
were determined by enzymatic methods using sphingosine kinase and
diacylglycerol kinase, respectively [17]. Total phospholipids present in
lipid extracts were also quanti¢ed [17].
2.6. Northern blotting analysis
Poly(A) RNA blots containing 2 Wg of poly(A) RNA per lane
from multiple adult human tissues (Clontech) were hybridized with
the 0.6 kb EcoRV/SphI fragment of pCR3.1-hSPHK1, which was gel-
puri¢ed and labeled with [32P]dCTP by random priming. Hybridiza-
tion in ExpressHyb bu¡er (Clontech) was carried out at 65‡C over-
night according to the manufacturer’s protocol. Blots were reprobed
with a human L-actin control probe (Clontech). Bands were quanti¢ed
using a Molecular Dynamics Phosphoimager.
3. Results and discussion
3.1. Cloning of hSPHK1
BLAST searches of the EST database identi¢ed a human
homologue of murine SPHK, EST AA026479, with similarity
to the 3P end of mSPHK1a. This sequence was used to design
speci¢c primers and 5P RACE was performed on mRNA ex-
tracted from HEK293 cells to obtain the full-length cDNA of
hSPHK1. The open reading frame encodes a protein with 384
amino acids, and 85% identity and 92% similarity to
mSPHK1a at the amino acid level (Fig. 1). We previously
found by sequence alignment that SPHKs from mouse, yeast
and Caenorhabditis elegans share several conserved blocks of
amino acids [15]. Similarly, hSPHK1 contains these conserved
regions (C1^C5, Fig. 1), including the invariant positively
charged motif, GGKGK, in the C1 domain, which may be
part of the ATP binding site of this novel class of lipid ki-
nases.
Fig. 1. Predicted amino acid sequence of hSPHK1 and alignment of the conserved domains. ClustalW alignment of SPHKs from mouse and
human. Identical and conserved amino acid substitutions are shaded dark and light gray, respectively. The conserved domains (C1^C5) are in-
dicated by lines and the invariant positively charged motif GGKGK by asterisks.
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3.2. hSPHK1 encodes a functional sphingosine kinase
HEK293 cells were transfected with expression vectors con-
taining hSPHK1 to determine whether it encodes a bona ¢de
SPHK. Modest levels of endogenous SPHK activity were de-
tected in cells transfected with an empty vector (Fig. 2A).
Twenty-four hours after transfection with pcDNA3.1-
hSPHK1, the SPHK activity increased approximately 600-
fold and remained at this level for at least 2 days. For com-
parison, a similar increase in activity was observed after trans-
fection with mSPHK1a (Fig. 2A). Similar results were ob-
tained when cells were transfected with hSPHK1 in pCR3.1.
In agreement with previous results with mSPHK1a [15],
hSPHK1 was stimulated by Triton X-100. Both membrane-
associated and cytosolic SPHK activity have been described in
mammalian tissues and cell lines [1,18^21]. In cells transfected
with hSPHK1, approximately 70% of the SPHK activity was
found in the cytosol and only about 30% was membrane-as-
sociated (Fig. 2A). Similarly, we previously found that the
majority of mSPHK1a activity was also expressed in the cy-
tosol [2,15]. Kyte^Doolittle hydropathy plots did not suggest
the presence of any potential hydrophobic membrane span-
ning domains in the primary structure of hSPHK1.
Transfection of HEK293 cells with hSPHK1 also resulted in
changes in levels of sphingolipid metabolites (Fig. 2B). Mass
levels of SPP increased 5.7-fold compared to cells transfected
with vector alone, with a 18% decrease in levels of both sphin-
gosine and ceramide. However, because intracellular ceramide
pools are much larger than sphingosine pools, the absolute
decrease of ceramide was greater than the decrease in sphin-
gosine mass. These results suggest that transfected hSPHK1 is
active in intact cells, and that kinase overexpression can alter
the intracellular balance of sphingolipid metabolites.
3.3. Substrate speci¢city of hSPHK1
The naturally occurring D-(+)-erythro-trans-isomer of sphin-
gosine and erythro-dihydrosphingosine (sphinganine) were the
best substrates for hSPHK1 (Fig. 3A). However, similar to the
speci¢city of mSPHK1a [15], sphingosine was more e⁄ciently
phosphorylated than sphinganine. Moreover, other sphingo-
Fig. 2. Activity of hSPHK1 expressed in HEK293 cells. A: HEK293 cells were transiently transfected with empty vector or vector containing
either mSPHK1a or hSPHK1. SPHK activity was measured in cytosol (¢lled bars) and particulate pellet (open bars) 24 h after transfection us-
ing sphingosine^BSA complexes or sphingosine^Triton X-100 micelles as substrate as indicated. SPHK activity in vector transfected cells was
84 þ 2 and 134 þ 27 pmol/min/mg using sphingosine^BSA complexes or sphingosine^Triton X-100 micelles as substrate, respectively. Data are
means þ S.D. and are representative of two independent experiments performed in triplicate. B: Changes in mass levels of SPP, sphingosine,
and ceramide. Mass levels of SPP, sphingosine and ceramide in cells transfected with empty vector (open bars) or vector containing hSPHK1
(¢lled bars) were measured after 24 h. Data are expressed as pmol/nmol phospholipid and are means þ S.D. of triplicate determinations.
Fig. 3. A: Substrate speci¢city of hSPHK1. HEK293 cells were
transfected with hSPHK1 and SPHK-dependent phosphorylation of
various sphingosine analogs or other lipids (50 WM) was measured
using cell lysates as enzyme source. DAG, diacylglycerol; PI, phos-
phatidylinositol; C2-CER, N-acetyl-sphingosine. B: DMS and DHS
are inhibitors of hSPHK1. SPHK activity in HEK293 cell lysates 24
h after transfection with hSPHK1 was measured with 10 WM SPP
in the absence or presence of 20 WM and 40 WM DMS or DHS.
Data are means þ S.D. of triplicate determinations and are expressed
as percent inhibition.
Fig. 4. Tissue-speci¢c expression of hSPHK1 by Northern blot anal-
ysis. Top panel: A hSPHK1 probe was hybridized to a poly(A)
RNA blot with the human tissues indicated at the top of each lane
as described in Section 2. Bottom panel: A L-actin probe was used
to reprobe the blot.
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lipids, including D,L-threo-dihydrosphingosine (DHS) and C2-
ceramide, as well as diacylglycerol and phosphatidylinositol
were not substrates (Fig. 3A). With D-erythro-sphingosine as
substrate, half-maximal velocity was found at 5 WM, in excel-
lent agreement with Km values previously determined with rat
kidney SPHK [14] and recombinant mSPHK1a [15]. DMS
and DHS have previously been used to inhibit SPHK and
block increases in SPP induced by various physiological stim-
uli [1,3,22]. Both of these sphingolipids also inhibited
hSPHK1 and similar to their inhibitory e¡ects on mSPHK1a
[15], DHS was slightly more potent than DMS (Fig. 3B).
3.4. Tissue distribution of hSPHK1 expression
The tissue distribution of SPHK1 mRNA expression in
adult human tissues was analyzed by Northern blotting
(Fig. 4). In most tissues, including adult brain, heart, spleen,
lung, kidney, and testis, a predominant 1.9 kb mRNA species
was detected. Expression was highest in adult liver, heart and
skeletal muscle. In comparison, we previously showed that
mSPHK1a expression is greatest in mouse spleen, lung, kid-
ney, testis and heart, with much lower expression in skeletal
muscle [15].
In summary, hSPHK1 is the human homolog of mSPHK1.
Based on EST sequences, hSPHK1 has been localized on
chromosome 17q25.2 at the marker stSG28540 (D17S785-
D17S836 Reference Interval, UniGene cluster Hs. 68061,
URL: http://www.ncbi.nlm.nih.gov/unigene/clust.cgi?org = hs
and cid = 68061). hSPHK1 belongs to a conserved family of
genes that is distinct from other known lipid kinases. Molec-
ular cloning and characterization of members of the SPHK
family should help to clarify their potential roles in various
human diseases as their product, SPP, has been implicated as
an important regulatory component of biological processes
including growth, survival, allergy, chemotaxis, and angiogen-
esis.
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